CMB International Securities  Equity Research Company Update
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
ACCESS KEY TO OUR REPORTS ON BLOOMBERG CMBR
China Healthcare Sector
Jill Wu CFA
Sam HU PhD
Mkt Cap (RMB mn)
Avg 3mths to (RMB mn)
52W HighLow (RMB)
Total Issued Shares (mn)
Source Bloomberg
Shareholding Structure
A-share public shareholders
H-share public shareholders
Source Bloomberg
Source Bloomberg
12-mth price performance
Source Bloomberg
Auditor Deloitte Touche Tohmatsu
Strengthening leading position in
global CROCDMO industry  13
SHSZ300 (rebased)
BUY (Maintain)
(Previous TP
RMB11473)
UpDownside
Core earnings slightly beat WuXi AppTec reported FY19 revenue of
RMB1287bn up 34% YoY inline with our estimate Non-IFRS net profit was
up 38% YoY to RMB24bn 4% above our estimate Meanwhile attributable
net profit decreased 18% YoY to RMB19bn 13% below our estimate mainly
due to the RMB107mn investments fair value loss and RMB98mn fair value
loss from convertible loans WuXi AppTec had 21744 employees as of end-
2019 up 23% YoY Fast expansion of staff team drives revenue growth given
that the CROCDMO business is labor-intensive Revenue contributed per
employee rose 10% YoY to RMB065mn in FY19 indicating improving
operating efficiencies
Phenomenal growth in CDMO and clinical services segment In FY19
CDMO revenue grew 39% YoY to RMB38bn contributing 29% of the total
projects 40 Phase III projects 117 Phase II projects and 756 early-stage
projects Revenue from clinical services increased 82% YoY to RMB11bn
thanks to both high organic growth and additional contribution from
acquisitions WuXi AppTec will further look for overseas acquisition
opportunities in clinical service area in order to enhance its global presence
in clinical service industry In FY19 ChinaUS-based laboratory services
delivered 27%30% YoY growth respectively ChinaUS-based laboratory
services accounted for 50%12% of the total FY19 revenue respectively
WuXi AppTec acquried 1200 new customers in FY19 while long-tail and
domestic customers contributed 68% of the total revenue in FY19
Share placement to bring sufficient funding for future expansion The
Company plans to raise cRMB65bn from placement of c75mn new A shares
and aims to place c682mn new H shares Total new issued shares will
share issuance WuXi AppTec will have rich funding for capacity expansion
and overseas acquisitions in our view
We lifted SOTP-based TP from RMB11473 to RMB11832 to reflect
strong long-term growth outlook for WuXi AppTec We forecast WuXi
AppTecs non-IFRS net profit to grow by 27%30%29% YoY in
FY20E21E22E respectively and attributable net profit to increase
54%32%31% YoY in FY20E21E22E Moreover WuXi AppTec
which will bring significant investment gains over the long term
Catalysts 1) Higher-than-expected earnings growth 2) Good acquisitions
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
Net profit (RMB mn)
YoY growth (%)
Change (%)
Consensus EPS (RMB)
Net gearing (%)
Current ratio (x)
Source Company data Bloomberg CMBIS estimates
WuXi AppTec (603259 CH)
Strong core business growth
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 CMBIS earnings revisions
Source Company data CMBIS estimates
Figure 2 CMBIS estimates vs consensus
Source Company data CMBIS estimates
Figure 3 Peers valuation
Rating (US mn)
Source Bloomberg CMBIS estimates as at 25 Mar 2020
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
ACCESS KEY TO OUR REPORTS ON BLOOMBERG CMBR
YE 31 Dec (RMB mn)
FY18A FY19A FY20E FY21E FY22E  YE 31 Dec (RMB mn)
FY18A FY19A FY20E FY21E FY22E
China-based lab services
7897 10109 12636  Depreciation and amortization
CMOCDMO services
8893  Change in working capital
US-based laboratory services
3121  Investment loss (gain)
Clinical research  other
2705  Other operating activities
21  Net cash from operating
Acquisition of subsidiaries
(60)  Other investing activities
Selling  distribution expenses
(917)  Net cash from investing
Administrative expenses
RD expenses
(941) (1177)  Net proceeds from shares issued
5446  Net borrowings
Acquisition of non-controlling
Finance costs net
(127)  Dividends and interests paid
60  Other financing activities
Net gain from FV changes
381  Net cash from financing
Pre-tax profit
(885)  Net change in cash
(100)  Cash at the beginning of the year
4914  Cash at the end of the year
YE 31 Dec (RMB mn)
FY18A FY19A FY20E FY21E FY22E  YE 31 Dec
FY18A FY19A FY20E FY21E FY22E
Non-current assets
6734  China-based lab services
705  CMOCDMO services
9559  US-based laboratory services
Clinical research and other
Other non-current assets
5138  Others
11807 12663 12639 14469 17281  Profit  loss ratios (%)
6744  Gross margin
2855  EBITDA margin
Trade and bills receivables
4950  Pre-tax margin
Prepayments deposits
and other receivables
123  Net margin
2609  Effective tax rate
8664  Balance sheet ratios
1604  Current ratio (x)
Trade and other payables
2622  Trade receivables turnover days
Other current liabilities
4438  Trade payables turnover days
Net debt to total equity ratio (%) Net cash
2 Net cash Net cash
Non-current liabilities
762  Returns (%)
Other non-current liabilities
4433  ROE
333  Per share
Shareholders equity
BVPS (RMB)
Source Company data CMBIS estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
ACCESS KEY TO OUR REPORTS ON BLOOMBERG CMBR
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities
or issuer that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities
in this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities
and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue
of this report (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve
covered in this report
CMBIS or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIS
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Securities Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Securities Limited (CMBIS) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary
of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIS
does not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives financial position
or special requirements  Past performance has no indication of future performance and actual events may differ materially from that which is contained in
the report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the
and strategies and encourages investors to consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIS solely for the purpose of supplying information to the clients of CMBIS or
its affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in
securities or enter into any transaction  Neither CMBIS nor any of its affiliates shareholders agents consultants directors officers or employees shall be
liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the information contained in this report  Anyone
making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable
information advices and forecasts on an AS IS basis  The information and contents are subject to change without notice CMBIS may issue other
publications having information and or conclusions different from this report  These publications reflect different assumption point-of-view and analytical
this report
on behalf of its clients from time to time Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with
and CMBIS will not assume any responsibility in respect thereof This report is for the use of intended recipients only and this publication may not be
reproduced reprinted sold redistributed or published in whole or in part for any purpose without prior written consent of CMBIS
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations
etc) of the Order and may not be provided to any other person without the prior written consent of CMBIS
For recipients of this document in the United States
This report is intended for distribution in the United States to major US institutional investors as defined in Rule 15a-6 under the US Securities Exchange
Act of 1934 and may not be furnished to any other person in the United States Each major US institutional investor that receives a copy of this research
report by its acceptance hereof represents and agrees that it shall not distribute or provide this research report to any other person
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as
defined in the Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced
by its respective foreign entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers
Regulations Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or an Institutional Investor as defined
in the Securities and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the
extent required by law Singapore recipients should contact CMBISG at 65 6350 4400 for matters arising from or in connection with the report